These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 23907409)

  • 41. Rituximab plus fludarabine and cyclophosphamide or other agents in chronic lymphocytic leukemia.
    Robak T; Lech-Maranda E; Robak P
    Expert Rev Anticancer Ther; 2010 Oct; 10(10):1529-43. PubMed ID: 20942624
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Huge kidneys in a patient with chronic lymphocytic leukaemia.
    Esposito P; Libetta C; Rampino T; Gregorini M; Margiotta E; Dal Canton A
    Br J Haematol; 2015 Feb; 168(4):470. PubMed ID: 25384540
    [No Abstract]   [Full Text] [Related]  

  • 43. Bendamustine for treatment of chronic lymphocytic leukemia.
    Chang JE; Kahl BS
    Expert Opin Pharmacother; 2012 Jul; 13(10):1495-505. PubMed ID: 22663160
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Single centre study of using bendamustine in the treatment of B-cell malignancies.
    Osmani AH; Masood N
    J Pak Med Assoc; 2013 Jun; 63(6):702-6. PubMed ID: 23901668
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Bendamustine: a new treatment option for chronic lymphocytic leukemia.
    Glode AE; Jarkowski A
    Pharmacotherapy; 2009 Nov; 29(11):1375-84. PubMed ID: 19857152
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients : A multicenter retrospective study on behalf of the Italian Lymphoma Foundation (FIL).
    Rigacci L; Puccini B; Cortelazzo S; Gaidano G; Piccin A; D'Arco A; Freilone R; Storti S; Orciuolo E; Zinzani PL; Zaja F; Bongarzoni V; Balzarotti M; Rota-Scalabrini D; Patti C; Gobbi M; Carpaneto A; Liberati AM; Bosi A; Iannitto E
    Ann Hematol; 2012 Jul; 91(7):1013-22. PubMed ID: 22349722
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Bendamustine compared to fludarabine as second-line treatment in chronic lymphocytic leukemia.
    Niederle N; Megdenberg D; Balleisen L; Heit W; Knauf W; Weiß J; Freier W; Hinke A; Ibach S; Eimermacher H
    Ann Hematol; 2013 May; 92(5):653-60. PubMed ID: 23340738
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treanda approved for chronic lymphocytic leukemia.
    Traynor K
    Am J Health Syst Pharm; 2008 May; 65(9):793. PubMed ID: 18436722
    [No Abstract]   [Full Text] [Related]  

  • 49. Bendamustine therapy in chronic lymphocytic leukemia.
    Masiello D; Tulpule A
    Expert Opin Pharmacother; 2009 Jul; 10(10):1687-98. PubMed ID: 19527193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Rapid development of infusion-related severe hypotension during rituximab therapy.
    Vo KH; Waddell JA; Suda KJ
    Ann Pharmacother; 2011 May; 45(5):e29. PubMed ID: 21505107
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New drugs: Ciclesonide, certolizumab pegol, and bendamustine hydrochloride.
    Hussar DA
    J Am Pharm Assoc (2003); 2008; 48(4):557-61. PubMed ID: 18653436
    [No Abstract]   [Full Text] [Related]  

  • 52. Bendamustine plus alemtuzumab is safe and feasible treatment for fludarabine refractory chronic lymphocytic leukaemia (CLL).
    Hill BT; Caimi P; Kindwall-Keller T; Habecker B; Kalaycio M
    Br J Haematol; 2014 Jan; 164(2):297-9. PubMed ID: 24131326
    [No Abstract]   [Full Text] [Related]  

  • 53. Cytotoxic and apoptosis-inducing effects of bendamustine used alone and in combination with rituximab on chronic lymphocytic leukemia cells in vitro.
    Ziolkowska E; Wolowiec D; Cebula-Obrzut B; Blonski JZ; Smolewski P; Robak T; Korycka-Wolowiec A
    Postepy Hig Med Dosw (Online); 2014 Dec; 68():1433-43. PubMed ID: 25531707
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Open-label bendamustine monotherapy for pediatric patients with relapsed or refractory acute leukemia: efficacy and tolerability.
    Fraser C; Brown P; Megason G; Ahn HS; Cho B; Kirov I; Frankel L; Aplenc R; Bensen-Kennedy D; Munteanu M; Weaver J; Harker-Murray P
    J Pediatr Hematol Oncol; 2014 May; 36(4):e212-8. PubMed ID: 24072240
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Bendamustine versus chlorambucil for the first-line treatment of chronic lymphocytic leukemia in England and Wales: a cost-utility analysis.
    Woods B; Hawkins N; Dunlop W; O'Toole A; Bramham-Jones S
    Value Health; 2012; 15(5):759-70. PubMed ID: 22867787
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Optimizing premedications in the prevention of bendamustine infusion-related reactions.
    Tombleson RL; Ho V; Sokol L; Pinilla J; Wetzstein GA
    Cancer Control; 2012 Jul; 19(3):245-7. PubMed ID: 22710900
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Phase III randomized study of bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukemia.
    Knauf WU; Lissichkov T; Aldaoud A; Liberati A; Loscertales J; Herbrecht R; Juliusson G; Postner G; Gercheva L; Goranov S; Becker M; Fricke HJ; Huguet F; Del Giudice I; Klein P; Tremmel L; Merkle K; Montillo M
    J Clin Oncol; 2009 Sep; 27(26):4378-84. PubMed ID: 19652068
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic lymphocytic leukemia-associated immune thrombocytopenia treated with rituximab: a retrospective study of 21 patients.
    D'Arena G; Capalbo S; Laurenti L; Del Poeta G; Nunziata G; Deaglio S; Spinosa G; Tarnani M; De Padua L; Califano C; Ferrara F; Cascavilla N
    Eur J Haematol; 2010 Dec; 85(6):502-7. PubMed ID: 20846302
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Phase I-II study of bendamustine in patients with acute leukemia and high risk myelodysplastic syndrome.
    Chacar C; Jabbour E; Ravandi F; Borthakur G; Kadia T; Estrov Z; Rios MB; Cortes J; Kantarjian H
    Clin Lymphoma Myeloma Leuk; 2012 Jun; 12(3):197-200. PubMed ID: 22578814
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Changing paradigms in the treatment of chronic lymphocytic leukemia.
    Foon KA; Hallek MJ
    Leukemia; 2010 Mar; 24(3):500-11. PubMed ID: 20033051
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.